biogen idec office address

Biogen Idec is a biotechnology company based in Cambridge, Massachusetts.

The company was founded by prominent biologists Sir Kenneth Murray, Charles Weissmann, and Phillip Sharp in 1978 in Geneva.

Biogen focuses on developing treatments primarily for immunology and neurology. Popular drugs include Avonex, which treats relapsing MS, Tysabrim, a treatment for MS and Crohn’s disease, Rituxan, which treats non-Hodkin’s lymphoma and rheumatoid arthritis, and Fumaden, a treatment for psoriasis.

The company has customers in over 90 countries worldwide.

In March 2020, Biogen employees unwittingly spread the COVID-19 virus from it’s home office in Massachusetts to Indiana, Tennessee, and North Carolina, after a company leadership meeting. 

Company shares also rose in March as investors looked for “safe” places to park their money and ride out the pandemic. 

Biogen Idec trades publicly on the NASDAQ under the ticker symbol BIIB, is a member of the S&P 500, is #375 in the Fortune 500, has 7,300 employees, and had $12.274 billion in revenue in 2017.

Biogen Idec

Biogen Idec is a biotechnology company based in Cambridge, Massachusetts.

The company was founded by prominent biologists Sir Kenneth Murray, Charles Weissmann, and Phillip Sharp in 1978 in Geneva.

History

Biogen focuses on developing treatments primarily for immunology and neurology. Popular drugs include Avonex, which treats relapsing MS, Tysabrim, a treatment for MS and Crohn’s disease, Rituxan, which treats non-Hodkin’s lymphoma and rheumatoid arthritis, and Fumaden, a treatment for psoriasis.

The company has customers in over 90 countries worldwide.

In March 2020, Biogen employees unwittingly spread the COVID-19 virus from it’s home office in Massachusetts to Indiana, Tennessee, and North Carolina, after a company leadership meeting. 

Company shares also rose in March as investors looked for “safe” places to park their money and ride out the pandemic. 

Biogen Idec trades publicly on the NASDAQ under the ticker symbol BIIB, is a member of the S&P 500, is #375 in the Fortune 500, has 7,300 employees, and had $12.274 billion in revenue in 2017.